Seth H.Z.  Fischer net worth and biography

Seth Fischer Biography and Net Worth

Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC. Previously, Mr. Fischer served as the Chief Executive Officer and as a Director of Vivus, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health from September 2013 to December 2017.

Prior to Vivus, Mr. Fischer served in various positions of increasing responsibility at Johnson & Johnson, most recently as company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Prior to that, he served as company Group Chairman, North America Pharmaceuticals, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals. Mr. Fischer’s operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including neurologic products for epilepsy and migraines and products in the analgesic, anti-infective, cardiovascular, psychiatric and women’s health areas. From May 2013 to May 2019, Mr. Fischer also served on the Board of Directors of BioSig Technologies, Inc.

Mr. Fischer brings to the Board over 37 years of experience in the pharmaceutical industry, including 29 years in various leadership roles at Johnson & Johnson.

What is Seth H.Z. Fischer's net worth?

The estimated net worth of Seth H.Z. Fischer is at least $6,206.78 as of February 6th, 2023. Mr. Fischer owns 6,026 shares of Spectrum Pharmaceuticals stock worth more than $6,207 as of April 2nd. This net worth evaluation does not reflect any other investments that Mr. Fischer may own. Learn More about Seth H.Z. Fischer's net worth.

How do I contact Seth H.Z. Fischer?

The corporate mailing address for Mr. Fischer and other Spectrum Pharmaceuticals executives is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. Spectrum Pharmaceuticals can also be reached via phone at (617) 586-3900 and via email at ir@sppirx.com. Learn More on Seth H.Z. Fischer's contact information.

Has Seth H.Z. Fischer been buying or selling shares of Spectrum Pharmaceuticals?

Seth H.Z. Fischer has not been actively trading shares of Spectrum Pharmaceuticals over the course of the past ninety days. Most recently, Seth H. Z. Fischer sold 5,711 shares of the business's stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $0.79, for a transaction totalling $4,511.69. Following the completion of the sale, the director now directly owns 29,066 shares of the company's stock, valued at $22,962.14. Learn More on Seth H.Z. Fischer's trading history.

Who are Spectrum Pharmaceuticals' active insiders?

Spectrum Pharmaceuticals' insider roster includes Seth Fischer (Director), Francois Lebel (Insider), Keith Mcgahan (Insider), and Thomas Riga (COO). Learn More on Spectrum Pharmaceuticals' active insiders.

Seth H.Z. Fischer Insider Trading History at Spectrum Pharmaceuticals

See Full Table

Seth H.Z. Fischer Buying and Selling Activity at Spectrum Pharmaceuticals

This chart shows Seth H Z Fischer's buying and selling at Spectrum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4k-$2k$0$2k$4kTotal Insider BuyingTotal Insider Selling

Spectrum Pharmaceuticals Company Overview

Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.03
Low: $1.03
High: $1.03

50 Day Range

MA: $1.01
Low: $0.94
High: $1.03

2 Week Range

Now: $1.03
Low: $0.32
High: $1.57

Volume

N/A

Average Volume

1,927,028 shs

Market Capitalization

$211.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15